The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Getting pharmaceutical R&D back on target
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,960
Suppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
The exploration of macrocycles for drug discovery — an underexploited structural class
Driggers, E. M., Hale, S. P., Lee, J., & Terrett, N. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2590 · Cited by 1,370
An empirical framework for binary interactome mapping
Venkatesan, K., Rual, J.-F., Vazquez, A., Stelzl, U., Lemmens, I., Hirozane-Kishikawa, T., Hao, T., Zenkner, M., Xin, X., Goh, K.-I., et al. (2009) · Nature Methods · doi:10.1038/nmeth.1280 · Cited by 904
Estimating the size of the human interactome
Stumpf, M. P. H., Thorne, T., de Silva, E., Stewart, R., An, H. J., Lappe, M., & Wiuf, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708078105 · Cited by 824
Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets
Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J., & Brownell, J. E. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3321 · Cited by 563
Edwards, A. M., Isserlin, R., Bader, G. D., Frye, S. V., Willson, T. M., & Yu, F. H. (2011) · Nature · doi:10.1038/470163a · Cited by 411
Frye, S. V. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.296 · Cited by 375
Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders
Drenth, J. P. H., & Waxman, S. G. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33297 · Cited by 370
Spending on new drug development1
Adams, C. P., & Brantner, V. V. (2010) · Health Economics · doi:10.1002/hec.1454 · Cited by 277
Will the Ubiquitin System Furnish as Many Drug Targets as Protein Kinases?
Cohen, P., & Tcherpakov, M. (2010) · Cell · doi:10.1016/j.cell.2010.11.016 · Cited by 271
Interactome under construction
Bonetta, L. (2010) · Nature · doi:10.1038/468851a · Cited by 232
The human genome and drug discovery after a decade. Roads (still) not taken
Isserlin, R., Bader, G. D., Edwards, A. M., Frye, S. V., Willson, T. M., & Yu, F. H. (2011) · arXiv (Cornell University) · doi:10.48550/arxiv.1102.0448 · Cited by 232
Activity-based probes: discovering new biology and new drug targets
Heal, W. P., Dang, T. H. T., & Tate, E. W. (2011) · Chem. Soc. Rev. · doi:10.1039/c0cs00004c · Cited by 193
Buchwald, P. (2010) · IUBMB Life · doi:10.1002/iub.383 · Cited by 133
Metz, J. T., & Hajduk, P. J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.166 · Cited by 100
Spending on New Drug DevelopmentPreprint
Adams, C., & Brantner, V. V. (2005) · SSRN Electronic Journal · doi:10.2139/ssrn.869765 · Cited by 66
Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor
Luca, L. D., Ferro, S., Gitto, R., Barreca, M. L., Agnello, S., Christ, F., Debyser, Z., & Chimirri, A. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.08.051 · Cited by 63
Magic bullets in nature's arsenal
Kritzer, J. A. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.407 · Cited by 34
Treatment of HIV infection with the CCR5 antagonist maraviroc
Kromdijk, W., Huitema, A. D. R., & Mulder, J. W. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003801081 · Cited by 33
Mapping of pharmacological space
Nisius, B., & Bajorath, J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.533654 · Cited by 19
New Frontiers in Chemical Biology
(2010) · Royal Society of Chemistry eBooks · doi:10.1039/9781849732178 · Cited by 8
Cited by
Gaulton, A., Hersey, A., Nowotka, M., Bento, A. P., Chambers, J., Mendez, D., Mutowo, P., Atkinson, F., Bellis, L. J., Cibrián-Uhalte, E., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1074 · Cited by 2,330
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
Escape from Flatland 2: complexity and promiscuity
Lovering, F. (2013) · MedChemComm · doi:10.1039/c2md20347b · Cited by 1,444
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
Metadata
- Authors
- Bunnage, M. E.
- Venue
- Nature Chemical Biology
- Published
- 2011-05-17
- Volume
- 7
- Issue
- 6
- Pages
- 335-339
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2030952396
- Cited by
- 258
- References
- 24
- FWCI
- 23.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.